MedTrace Logo

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT06335914 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-12

No results posted yet for this study

Summary

This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.

Conditions

Interventions

DIAGNOSTIC_TEST

Ga 68 PSMA-11 PET

Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer

DIAGNOSTIC_TEST

18F-DCFPyL PET

Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.

DIAGNOSTIC_TEST

FDG PET

Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Di (Maria) Jiang · Princess Margaret Cancer Centre/University Health Network

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2029-03-04
Completion
2029-09-04

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06335914 on ClinicalTrials.gov